INTRODUCTION
The etiology of malignancy-associated hypercalcemia (MAH)' is uncertain. Immunoreactive PTH (iPTH) levels are either inappropriately high (1) or undetectable (2) depending on the radioimmunoassay (RIA) used. A recent study (2) in which 41/50 consecutive patients with MAH had elevated nephrogenous cyclic AMP (NcAMP) (a finding previously considered to be specific for hyperparathyroidism) has rekindled interest in the possibility that MAH in many patients may be due to secretion of a PTH-like substance.
In this report we describe a protein factor secreted by cultured renal carcinoma cells from a patient with MAH. This factor activates renal adenylate cyclase apparently via an interaction with the PTH receptor, but is not recognized by multiple PTH antisera. The same cells produce both subcutaneous tumors and marked hypercalcemia in nude mice. The origin and properties of this cell line suggest that the factor it secretes may be representative of the etiologic agents producing hypercalcemia in patients with MAH and high NcAMP.
METHODS
Cell lines. Line 786-0 was derived from a primary renal adenocarcinoma in a 58-yr-old man with multiple lung metastases but without evidence of bone metastases. The patient had a total serum calcium of 10.6-12.5 mg/dl, albumin 3.0 g/dl, and phosphorus 3.5 mg/dl. The culture methods and a complete characterization of the cell line have previously been published (3) .
Tumor production in nude mice. Medium from 786-0 cells produced activation of renal adenylate cyclase, and the dose-response curve produced by multiple dilutions of medium was parallel to that obtained with bPTH(1-34) (Fig 2) . In contrast, medium from 253-J cells produced no adenylate cyclase activation. Media from four additional human renal carcinoma cell lines and from a primary culture of normal human kidney cells were likewise inactive (not shown). [8Norleucyl, '8norleucyl, 34tyrosinyl]-bPTH(3-34)amide (Peninsula Laboratories, San Carlos, CA), a competitive antagonist of PTH (9), completely abolished adenylate cyclase activation produced by the 786-0 cell factor and by bPTH(1-84) (Fig. 3) . Trypsin treatment of the factor also abolished its bioactivity (data not shown).
Gel filtration chromatography of 786-0 medium disclosed two components of PTH-like bioactivity (Fig. 4) . A major component was eluted between the 125I-bPTH(1-84) marker and monomeric BSA, the later peak at absorbance of 280 nm. A minor component of bioactivity was eluted after '251-bPTH(l-84), but well before 125I-bPTH(I-34).
Biologically active material was assayed in four PTH RIA with differing regional specificities. No iPTH was found despite addition of medium with enough bioactivity to exceed the detection limits of the RIA by 100-to 1,000-fold. Furthermore, iPTH was not found in gel filtration column effluent fractions corresponding to either the major or minor component of bioactivity (data not shown).
DISCUSSION
That hypercalcemia in the nude mouse bearing human tumor cells has a humoral basis is evidenced by the rapid normalization of serum calcium following resection of tumor. Although the humoral mechanism remains undefined, 786-0 cells in culture were found to elaborate a factor that produced a PTH-like biological effect in vitro, whereas no such factor was released by 253-J cells that failed to produce hypercalcemia in vivo. Clearly the most parsimonious interpretation of the above observations, that the PTH-like protein causes hypercalcemia, must be explored. The precise relationship of the 786-0 factor to PTH is uncertain. Its activity in a PTH-specific assay and the inhibition produced by a PTH antagonist that acts competitively at PTH receptors (9) provides strong evidence that the 786-0 factor interacts with renal PTH receptors. Yet the factor is distinguishable from native human PTH both by its failure to cross-react in four region-specific PTH RIA and by its larger apparent molecular size upon gel filtration chromatography. Nor is the protein identical to either of the known precursor forms of PTH, prepro-or pro-PTH, inasmuch as these have substantial immunoreactivity in COOH-region PTH RIA (11) , and amino-terminal extensions, as in the precursors, markedly reduce renal adenylate cyclase-stimulating activity (12) . It is conceivable that the 786-0 factor is an altered PTH gene product lacking accessible sites for interaction with PTH antibodies. Alternatively, the factor could be a distinct gene product that interacts with PTH receptors due to sequence and/or conformational homology with PTH. Less likely is the possibility that the factor acts via a distinct receptor, even though the PTH antagonist inhibits adenylate cyclase activation by the factor.
PTH-like
Secretion of high-molecular weight PTH-like substances may be a relatively frequent occurrence in patients with MAH. MAH sera were found to contain large forms of iPTH, the quantity of which was correlated with serum calcium (13) . With a cytochemical bioassay, sera of three patients with MAH and elevated NcAMP excretion contained a PTH-like substance larger than PTH(1-84) (14) . It has been reported in preliminary form that squamous carcinomas from two patients with MAH contained a high-molecular weight (-70,000) substance that stimulated renal adenylate cyclase (15) . Stewart et al. (2) reported that 80% of unselected patients with MAH had elevated excretion of NcAMP, despite normal or low circulating levels of iPTH. Given the close relationship between PTH-responsive renal adenylate cyclase and NcAMP, it is possible that such patients are hypercalcemic as the result of a humoral tumor-derived substance similar or identical to that reported here. If so, the in vitro cell system we have described will permit the identification of the responsible factor. The nude mouse model of MAH will also facilitate study of the human syndrome and testing of new therapeutic modalities, such as specific PTH an-Fraction no.
FIGURE 4 Chromatography of 786-0 cell medium on Bio Gel P-150. Medium (160 ml) was concentrated and fractionated by ascending flow (6.5 ml/h) on 2.6 X 90-cm columns at 40C in 0.2 M ammonium acetate (pH 4.6) (10). Biologically inactive, 1251-labeled bPTH(1-84) and (1-34), as well as Na'"I were added to the sample as markers before chromatography. Fractions (5.5 ml) were lyophilized for 4 d and resuspended in 10 mM acetic acid/0.001% BSA for bioassay. Total recovery of bioactivity >50%.
tagonists, which may ultimately have widespread application to the treatment of patients with MAH. 
